International consensus recommendations for smoking cessation in type 2 diabetes from the DiaSmokeFree Working group
Methodological detailsmultidisciplinary panel, structured multi-stakeholder consensus process, GRADE where feasible, AGREE reporting framework, Panel of 35 experts from 13 countries
- Multidisciplinary panel
- Structured multi-stakeholder consensus process
- GRADE where feasible
- AGREE reporting framework
- Panel of 35 experts from 13 countries
Recommendations
As issued by the authors
Varenicline is the only medication that can be strongly recommended; evidence on pharmacological treatment in T2D is limited
Intensive, individualized interventions combining pharmacotherapy, behavioral support and relapse management are more effective than brief interventions
Drug-smoke interactions may require dose adjustments (e.g., drugs affected by CYP1A2, UGT enzymes or renal transporters)
Smoking cessation substantially reduces the increased cardiovascular, stroke and macrovascular risk associated with smoking in T2D
Original publication
International consensus recommendations for smoking cessation in type 2 diabetes from the DiaSmokeFree Working group. Diabetes Res Clin Pract. Published 28 August 2026. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →